Andor Health’s ThinkAndor Advances AI-Native Connected Care
ORLANDO, Fla., July 30, 2026 Andor Health announced that its AI-native clinical services operating platform, ThinkAndor®, has reached General...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ORLANDO, Fla., July 30, 2026 Andor Health announced that its AI-native clinical services operating platform, ThinkAndor®, has reached General...
REHOVOT, Israel, June 2, 2026 Evogene Ltd. has announced the successful completion of the first-in-human Phase 1 clinical study...
SAN DIEGO, June 1, 2026 Resmed has completed its acquisition of Noctrix Health, significantly expanding its clinical sleep health...
PALO ALTO, Calif., May 14, 2026 Glooko, Inc. announced that the U.S. Food and Drug Administration has granted 510(k)...
WARSAW, Ind., December 16, 2025 — Zimmer Biomet Holdings, Inc., a global leader in medical technology, has entered into...
